Codexis, Inc. Q3 2026 Earnings Conference Call - CODEXIS INC

Financial Performance:

• Q3 2026 revenue totaled $19.3 million, a 124% increase year-over-year from $8.6 million in Q3 2025, marking the fourth consecutive quarterly on-target performance.
• Product gross margin reached 74.5% in Q3 2026, continuing an upward trend with management anticipating full-year 2026 gross margins in the low 70s.
• R&D expenses decreased to $12.6 million from $13.9 million in the prior year period, driven by lower employee-related costs and reduced lab supplies.
• SG&A expenses fell to $10.1 million from $11.2 million, attributed to reduced headcount, lower stock-based compensation, and allocated cost reductions.
• Net loss narrowed significantly to $8.1 million in Q3 2026 compared to $19.6 million in the prior year.
• Cash position stands at $72.7 million in cash, cash equivalents, and short-term investments (down from $78.2 million at year-end 2025).
• Capital raises included a $25 million net equity offering in Q3 and a $42.5 million drawdown from a new $60 million term loan to refinance existing debt.
• 2026 full-year revenue guidance remains unchanged at $72 million to $76 million; cash runway extends through 2028.

Guidance and Future Outlook:

• Management projects moving toward 500-gram production scale within the coming months, with a subsequent rapid transition to kilo-scale.
• Construction on a new GMP production facility is scheduled to begin in the near term.
• Focus on industrialization includes reducing cycle times by 40% and optimizing for high-quality output at 100-gram scale.
• Management anticipates a shift from technical feasibility discussions to commercial deployment and regulatory strategy with customers.
• The company expects to secure higher-value contracts and innovative licensing deals in 2027, building on momentum from late 2026 agreements.
• Small-molecule biocatalysis business is on pace to exceed revenues of each of the last three years, driven by new product approvals and label expansions.

Business Segments and Product Lines:

• EcoSynthesis Platform: Successfully scaled to 100-gram production with high-quality oligonucleotides; achieved a 3-4x potency increase in stereocontrolled siRNA compared to stereorandom controls.
• New Capabilities: Added tissue-targeting molecule incorporation to the standard workflow and developed methods for enzymatic synthesis without starter oligos.
• Biocatalysis Products: Q1-Q3 product sales surged 78.5% year-over-year, led by the proprietary enzyme CDX049.
• Pipeline: 12 programs in Phase II/III clinical development with data readouts expected on seven trials over the next two years.
• Commercial Agreements: Signed feasibility study with a pioneer to test stereo-defined fragments; secured evaluation agreement with a large biopharma to assess ligation strategies and pilot-scale technology transfer.

Market and Competitive Landscape:

• Industry dialogue has shifted from "proof of concept" to "implementation," with traditional solid-phase chemistry facing limitations in scaling for large patient populations.
• EcoSynthesis offers a 70% more capital-efficient manufacturing approach compared to legacy methods, particularly attractive to new entrants and CDMOs.
• Platform demonstrates superior crude purity (>90% at 100g scale) and consistent quality across scales, addressing key industry bottlenecks.
• Engaging with both innovators (pharma/biotech) and CDMOs, with the latter seeking capital-efficient strategies to re-enter or expand in the oligonucleotide market.
• Regulatory environment is viewed as collaborative, with FDA showing strong interest in the platform's purity and stereochemical advantages.

Risks and Challenges:

• Forward-looking statements regarding milestones, revenue, and product launches are subject to risks and uncertainties that could materially affect results.
• Dependence on the successful industrialization of the EcoSynthesis platform to kilo-scale and beyond for future revenue realization.
• Execution risks associated with new facility construction and technology transfer into client pilot plants.
• Potential delays in regulatory clarity regarding comparability arguments for stereo-controlled products versus traditional chemical synthesis.

Management Commentary and Tone:

• Management expressed high confidence and pride in Q3 achievements, describing the results as "solid" and the technology's potential as "disruptive."
• Tone was optimistic regarding the industry's acceptance of enzymatic approaches, noting a transition from curiosity to serious deployment planning.
• CEO Allison Moore and CSO Stefan Lutz emphasized the "robust foundation" laid over three years and the predictive nature of their process data.
• CFO Georgia Herbez highlighted the strengthened balance sheet and efficient capital usage as key to sustaining operations through 2028.

Analyst Questions and Answers:

• FDA Interaction: Management confirmed a successful late-September meeting focusing on enzyme specifications, siRNA product specs, and comparability arguments; FDA is described as "extremely engaged" and aligned with the platform's purity.
• Scale-up Strategy: To reach 500 grams, the company plans to synthesize hundreds of grams in fragments and stitch them via ligation, avoiding the physical limitations of solid-phase synthesis which caps at 7-10 kg per batch.
• Quality Differentiation: EcoSynthesis operates in mild aqueous conditions, reducing product damage compared to the harsh conditions of solid-phase chemistry, resulting in easier purification.
• Customer Funnel: Interest has shifted from clinical to pre-clinical and commercial stages, particularly driven by the new potency data from stereocontrol; CDMO conversations are described as "serious" rather than curious.
• Deal Timing: While specific announcement dates are hard to predict, management highlighted two significant signed agreements (one for stereo control, one for ligation) and expressed hope for additional announcements in the next quarter.

Other Key Points:

• The 100-gram synthesis demonstrated a strong predictive relationship between process and product performance, validating process understanding for future scaling.
• Three drugs using Codexys' enzymes were approved this year, including two potential blockbusters that will launch soon.
• The company is pursuing technology transfer into client pilot plants to demonstrate the small footprint and aqueous process integration capabilities.
• Management noted that traditional chemical synthesis quality can degrade as scale increases due to physical limitations, whereas enzymatic synthesis is not subject to these same barriers.